Patents by Inventor A. Katrina Loomis

A. Katrina Loomis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090286729
    Abstract: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.
    Type: Application
    Filed: October 30, 2008
    Publication date: November 19, 2009
    Inventors: Jeffrey S. Bishop, A. Katrina Loomis, Daniel J. Monticello, Philip T. Pienkos
  • Patent number: 7470769
    Abstract: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: December 30, 2008
    Assignee: Molecular Logix, Inc.
    Inventors: Jeffrey S. Bishop, A. Katrina Loomis, Daniel J. Monticello, Philip T. Pienkos
  • Patent number: 7084246
    Abstract: The present invention features polypeptides that have at least 90% amino acid identity to wild-type epidermal growth factor, and also have epidermal growth factor biological activity that is greater than the biological activity of wild-type epidermal growth factor.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: August 1, 2006
    Assignee: Molecular Logix, Inc.
    Inventors: Wayne M. Coco, Philip P. Pienkos, A. Katrina Loomis